Kerecis Acquisition, Valuation, Funding & Investors

FibroGen is a biopharmaceutical company discovering therapies based on hypoxia-inducible factor and connective tissue growth factor biology for anemia, fibrosis, and cancer. Its flagship product roxadustat, a HIF-PH inhibitor, received approval in China in 2018 and Japan in 2019 for anemia in chronic kidney disease, with ongoing global trials. Headquartered in San Francisco, California, FibroGen partners with AstraZeneca and Astellas for commercialization in multiple regions.

BenevolentAI is a London-headquartered clinical-stage company using artificial intelligence for drug discovery, listed on Euronext Amsterdam under BAI. Its platform supports 13 named programs and over 10 exploratory ones, with collaborations including AstraZeneca on respiratory and cardiovascular diseases. Facilities in Cambridge and New York enable wet-lab validation of AI-generated candidates.

Rakuten Medical is a clinical-stage biotechnology company developing photoimmunotherapy for cancer treatment using its Alluminox platform. Its lead product, ASP-1929, gained approval in Japan for head and neck cancer. Rakuten Medical conducts global trials and offers expanded access programs via rakuten-med.com across multiple countries.

ArsenalBio is a South San Francisco-based, clinical-stage cell therapy company that engineers CAR T-cell therapies using CRISPR-based genome editing and logic-gating technology. Its pipeline targets solid tumors including ovarian, kidney, and prostate cancers, with its lead candidate, AB-2100, in Phase 1/2 trials for clear-cell renal cell carcinoma under a collaboration with Bristol-Myers Squibb. The platform is designed to address T-cell exhaustion, tumor specificity, and genome toxicity, challenges that have limited CAR T therapies in solid tumors.

BioRay Pharmaceuticals is a Shanghai-headquartered biopharma with R&D centers in Taizhou, Hangzhou, San Diego, and over 1,400 employees focused on immunology therapies. It commercializes three products in China for autoimmune diseases including Telitacicept for SLE, with a pipeline of 20 preclinical and 10 clinical assets targeting cancer and inflammation. Founded in 2010, BioRay operates GMP facilities for full-cycle development.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

Biomat USA is a network of plasma collection centers operated by Grifols producing source plasma for therapies treating hemophilia, immune deficiencies, and trauma. Centers in the United States offer donor compensation and community support programs, contributing to global supplies of albumin, immunoglobulins, and clotting factors.

Brickell Biotech is a clinical-stage pharmaceutical company developing prescription therapeutics for skin diseases, with sofpironium bromide as its lead candidate for primary axillary hyperhidrosis. The pipeline advances topical treatments through Phase 3 trials. Leadership draws from roles at companies launching Cialis, Taltz, Gemzar, Prozac, Cymbalta, and Juvederm. Headquartered in Raleigh, North Carolina, Brickell Biotech trades on Nasdaq under BBI.

Equashield is a medical device manufacturer specializing in closed system transfer devices that prevent exposure to hazardous drugs during compounding and administration. Its flagship product, the Equashield PRO platform, features a needle-free, mechanically closed system compliant with USP <800> standards for handling antineoplastic agents. Headquartered in Port Washington, New York, with operations originating from Israel since its founding in 2007, the company supplies over 1,000 hospitals across North America, Europe, and Asia. Equashield holds FDA 510(k) clearance and NIOSH certification, and it partners with major distributors like McKesson and Cardinal Health to protect pharmacists and nurses from aerosols and vapors.

Everlywell is an Austin, Texas-based digital health company, founded in 2015, that sells at-home lab testing kits for conditions including cholesterol, thyroid health, fertility, testosterone, food sensitivities, and sexually transmitted infections, with results reviewed by physicians through partnered labs. The company added COVID-19 sample collection kits in March 2020, scaling to handle up to 250,000 tests per week during the pandemic. Its direct-to-consumer model combines e-commerce sales of test kits with lab fees, physician review, and subscription revenue for repeat testing.

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Arcs Co Ltd is a Japan-based company principally engaged in the supermarket business. The company also operates other businesses through subsidiaries, including tourism, building maintenance, real estate leasing, property and casualty insurance and life insurance agency, wholesale, food manufacturing, industrial and general waste collection, and construction businesses. The supermarket segment offers a broad range of merchandise, including foods, apparel, and housing-related products.

Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.

Wilson Wolf Corporation is a medical device manufacturer headquartered in Eden Prairie, Minnesota, producing gas-permeable cell culture flasks and bioreactors for mammalian cell expansion in applications like monoclonal antibody production, stem cell therapy, and tissue engineering. Established in 1998, the company supplies platforms used by researchers at Mayo Clinic and universities for immunotherapy and diabetes research.

Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.

Kallyope is a New York City-based biotech company developing gut-brain axis therapeutics for metabolic and neurological disorders. Founded in 2016, it raised $330 million in funding and employs 150 scientists from Rockefeller University and Pfizer. Its pipeline includes KGX323 for obesity in Phase 1 trials and candidates for IBS and migraine, using single-cell sequencing of 1 million gut neurons.

GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

Alzheon is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for Alzheimer's disease and related dementias. Its pipeline includes ALZ-801, a prodrug of tramiprosate in Phase 3 trials targeting amyloid oligomers, and ALZ-901 for combination therapy. Founded in 2011 and based in Framingham, Massachusetts, Alzheon has raised over $100 million and collaborates with institutions like Brigham and Women's Hospital.